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1. Introduction 
Arterial hypertension is the leading cause of mortality in the world [1]. It is estimated that 25 
to 35 % of modern populations suffer from this condition [2-4]. Hypertension is the major 
risk factor for the most common cardio vascular diseases which are a major cause for 
morbidity and mortality. Depending on the stage of hypertension, it dramatically increases 
the individual risk for heart failure, heart attack, stroke or chronic kidney failure if not 
treated adequately [5]. Since hypertension is usually not directly linked to specific 
symptoms, it is one of the most insufficiently treated diseases in the population with only 
10-20 % of patients with controlled blood pressure levels [4]. It is estimated that the 
prevalence of hypertension is going to increase within the next decades. Aging populations 
contribute significantly to this trend [6]. Due to its impact on public health, it already is a 
major burden for modern societies [7].  
New strategies and treatment options have to be evaluated in order to slow or prevent the 
rise in hypertension related morbidity and mortality. This chapter focuses on the role of the 
sympathetic nervous system in the pathogenesis of hypertension. After almost half a decade 
with only minor advancements in this field, sympathetic overactivity has been recognized as 
a major contributor to hypertension [8]. Many secondary causes can increase sympathetic 
activity which can lead to hypertension. Beyond the initial contribution, sympathetic 
overactivity can sustain hypertension. Therefore the sympathetic nervous system plays a 
role in the acute and chronic pathogenesis of hypertension. Understanding the mechanisms 
involved in the regulation of the sympathetic nervous system is currently leading to novel 
approaches in hypertension treatment.  
2. Anatomy of the sympathetic nervous system 
2.1 Efferent sympathetic neurons 
Sympathetic innervation origins from the intermediolateral cell column of the spinal cord. 
Preganglionic neurons range from the thoracic to the lumbar parts (T1-L2). These short 
neurons usually travel to the paravertebral ganglia where they connect to the postganglionic 
neurons. Those postganglionic neurons sympathetically innervate most organs such as 
heart, kidney and blood vessels (Fig. 1). Sympathetic nerve endings release a variety of 
neurotransmitters notably norepinephrine, neuropeptide Y (NPY) and adenosine 
triphosphate (ATP) [9, 10]. 
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Sympathetic overactivity is a major contributor to arterial hypertension which is one of the 
leading causes of stroke, chronic kidney failure, left ventricular hypertrophy and sudden 
cardiac death. 
 
 
Fig. 1. Schematic of sensory, afferent and sympathetic efferent neurons and target organ 
innervation.   
One of the distinct features of the sympathetic nervous system is the immediate regulation 
of peripheral vascular resistance through adaptation of the vascular tone. Besides this 
immediate action on blood pressure control through vasoconstriction, release of sympathetic 
neurotransmitters contribute to adaptive mechanisms through regulation of cell 
proliferation, transformation and apoptosis which are blood pressure independent [11-14].   
2.2 Afferent sympathetic nerve activity 
Besides the efferent innervation, sensory afferent neurons travel from target organs to the 
sympathetic nuclei of the central nervous system (CNS). These afferent nerves have been 
extensively described for the kidney but can also be found in the heart [15]. The pathogenesis 
of this sympathetic activation was elucidated in several animal models [16]. Afferent nerves 
are activated by baro- or chemoreceptors in ischemia or inflammation [17]. They travel along 
the renal artery and insert the posterior horn of the spinal cord at the level of TH6-L3 from 
where they travel to the sympathetic nuclei of the CNS (Fig.1). Neurotransmitters of these 
afferent neurons are ATP, substance P and calcitonin-gene related peptide (CGRP)[18].  
The renin-angiotensin-aldosterone system (RAAS) contributes to the central nervous 
feedback in sympathetic activation. Especially angiotensin II and nitric oxide (NO) are 
important effectors of this system [19]. Inhibition of the RAAS leads to a decrease in efferent 
sympathetic activity in chronic kidney disease patients [18]. Not all inhibitors of the RAAS 
can penetrate through the blood-brain barrier, therefore peripheral actions of angiotensin II 
are likely to affect afferent signal transduction.  
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Renal ischemia leads to a release of adenosine as a paracrine transmitter. This leads to a 
potent activation of afferent neurons [17]. Interestingly, in an animal model, already minor 
kidney injury through local injection of phenol leads to a permanent neurogenic 
hypertension [20]. Severing afferent and efferent sympathetic nerve fibers prevents 
hypertension in an animal model of chronic kidney injury [21]. Independent from CNS-
effects, chronic kidney injury leads to an increase of presynaptic norepinephrine release in 
the heart and kidney. This might be due to an increase in angiotensin II through RAAS 
activation [22-24]. However, it is still unclear which renal mechanisms contribute to a 
sustained activation of renal afferent neurons. 
3. Detection of increased neuronal activity 
3.1 Microneurography 
Microneurography has been established at the university of Uppsala (Sweden) by Karl-
Erik Habbarth und Åke Vallbo [25]. The sympathetic nerve activity can be measured by 
insertion of a micro electrode into a peripheral nerve (mostly peroneal nerve) [26].  
 
 
Fig. 2. Multiunit activity sympathetic nerve activity (MSNA) of the sural nerve.  Kidney 
transplant patients show an increased sympathetic nerve activity despite normal serum 
creatinine levels. Only nephrectomy of the native kidneys is able to normalize the activity 
compared to healthy controls (modified from [28] ). 
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Multiunit activity sympathic nerve activity (MSNA) is equivalent to the sympathetic 
activity. This activity is measured as “bursts” per minute. Using this method, the concept 
of the kidney as a pacemaker of sympathetic activity could be very well established. 
Converse et al. analyzed the sympathetic activity in dialysis patients vs. healthy controls 
[27]. Interestingly, in kidney transplant patients with normal serum levels of creatinine 
and urea, the sympathetic overactivity persisted. Only bilateral nephrectomy was able to 
abolish the pathologic sympathetic overactivity (Fig. 2) [28]. 
3.2 Norepinephrine release 
Besides microneurography, norepinephrine release can be used to estimate the activity of 
the sympathetic nervous system. This concept has been established by Murray Esler from 
Melbourne, Australia [29]. Norepinephrine can be measured in blood samples. Also local 
norepinephrine release can be quantified in tissue samples from kidney and heart.  
The heart is an important target organ of sympathetic activity. Especially patients with end 
stage renal disease show a dramatic and early increase of cardiovascular events. Zocalli et 
al. could demonstrate that norepinephrine and NPY serum levels correlate with the patient 
mortality (Fig. 3) [30, 31]. 
 
 
 
Fig. 3. Serum norepinephrine levels correlate well with the incidence of cardiovascular 
events in end stage renal disease patients (n = 228 patients on haemodialysis). Kaplan-Meier 
survival curves for cardiovascular events (fatal and nonfatal) in patients below and above 
75th percentile of serum norepinephrine (5.57 nmol/L) (from [30]). 
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3.3 Modulation of sympathetic activity 
The sympathetic nervous system allows for rapid adaptation of the body to current events. 
Orthostatic reaction is a well examined example of immediate activation of the sympathetic 
nervous system [32]. Besides pain, stress and urgency, changes in temperature, blood 
oxygenation and ambient sound level lead to a change in sympathetic activity [15, 32]. 
Instead of immediate alterations of sympathetic activity, it appears feasible that long-term 
change in sympathetic activity is the underlying mechanism which contributes to the 
development of hypertension. Aging people show an increase in sympathetic activity with 
an increase of MSNA of 1 burst/min per year [33]. Although female subjects are 
characterized by a lower MSNA, they exhibit a more significant annual increase [34]. It is 
likely that the increase in MSNA contributes to the development of hypertension in the 
aging population, since the prevalence of hypertension increases with age. There is a tight 
correlation between blood pressure and MSNA in subjects older than 40 which does not 
occur in younger patients (Fig. 4.) [34]. This might be due to diminished compensatory 
mechanisms in the elderly population (endothelial dysfunction, diminished baroreflex, etc.).     
Sympathetic overactivity is the pathogenic link between hear failure, sleep apnea, metabolic 
syndrome and hypertension.  
 
 
 
Fig. 4. Correlation between MSNA and mean arterial blood pressure in female subjects <40 
and ≥ 40 years of age. A correlation between blood pressure and MSNA cannot be found 
until the age of 40 (modified from [34]). 
3.4 Sympathic overactivity in chronic heart failure   
Chronic heart failure is associated with an increased sympathetic activity [35]. There is a 
tight correlation between severity of heart failure and MSNA. However, MSNA does not 
allow direct conclusion on the degree of heart failure. Due to different mechanisms of 
sympathetic activation, high MSNA can also be found in patients with only mild to 
moderate heart failure [36].  
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The rise in MSNA causes an increase of norepinephrine release in the myocardium. The 
increased release of norepinephrine contributes to the increased risk of arrhythmogenic 
cardiac events and left ventricular hypertrophy.  
In an animal model with genetically determined sympathetic overactivity (ǂ2-adrenoceptor 
knockout - decreased adrenergic auto inhibition), increase of left ventricular mass and heart 
failure can be observed [37]. 
Hypernatremia is a common finding in severe chronic heart failure. This leads to an 
activation of the RAAS and sympathetic nervous system.  However, the increase in 
sympathetic activity can already be observed in mild to moderate chronic heart failure. The 
underlying cause is not well understood. This might be linked to a change in baroreflex 
sensitivity or a maladaptation of the cardiopulmonary reflex [35]. 
A left ventricular systolic dysfunction with an increase of cardiopulmonary filling pressure 
can trigger sympathetic activity. Obesity and sleep apnea add to this condition.  
Therefore, a goal in chronic heart failure has to be the inhibition of the self-sustaining pacing 
of sympathetic activity, in order to reduce the cardiovascular mortality.  
3.5 Sympathetic overactivity in sleep apnea 
Sleep related respiratory dysfunction is much more common in patients with hypertension 
compared to the common population [18]. Some authors estimate that every second patient 
with hypertension is prone to sleep related respiratory dysfunction [38]. An increase in 
blood pressure is almost always observable in sleep apnea patients. Apnea causes an 
immediate increase in sympathetic activity which is the underlying cause of the increase in 
blood pressure [39]. Chemo-receptors within the carotid body (glomus caroticum) are 
activated due to hypoxia. Those chemo-receptors can directly activate the sympathetic 
nervous system. [18]. 
In chronic sleep apnea, this activation of the sympathetic nervous system persists during 
daytime which results in increased MSNA and norepinephrine release [40]. Intermittent 
hypoxia leads to a sustained increase in blood pressure in an animal model. Denervation of the 
carotid body abolishes the blood pressure increase after hypoxia [41]. Desensitizing chemo-
receptors through respiration of 100 % oxygen leads to a decrease in sympathetic activity, 
heart rate and blood pressure in wake sleep apnea patients but not in healthy controls [42]. 
Apparently, a sustained activity of chemo receptors contributes to the stimulation of the 
sympathetic nervous system while awake which is leading to hypertension.  
Despite chemoreceptors, baroreceptors play a central role in regulation of the cardiovascular 
system. A dysfunction of baroreceptors can be observed in sleep apnea patients similar to 
chronic heart failure patients. In a canine animal model of sleep apnea, the baroreflex is 
adjusted to higher blood pressure levels [43]. Obstruction of the respiration at night leads to 
a sustained hypertension at daytime [44]. Continuous Positive Airway Pressure (CPAP) 
therapy  is able to abolish or reduce sleep apnea. Night- and day-time sympathetic 
overactivity can be significantly reduced through this therapy [40]. 
3.6 Sympathic overactivity in metabolic syndrome 
The increased sympathetic activity in metabolic syndrome patients contributes to the 
increased cardiovascular risk in this patient group [45]. In overweight patients, sympathetic 
overactivity appears to be linked to a dysfunction of the baroreflex [46]. This is also linked to 
the distribution of body fat mass. Accumulation of visceral fat is characterized by an 
increase in MSNA and cardiovascular risk [45]. 
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Compared to healthy individuals, overweight people suffer significantly more often from 
hypertension and show an increased risk for the development of type 2 diabetes. An 
increased MSNA can also be observed in patients with type II diabetes  [47].  
The underlying cause for this interacting pathogenesis is unknown. Hyperinsulinemia 
appears to play an important role. For instance, administration of insulin in an increasing 
dose was able to increase MSNA in euglycemic individuals [48]. 
3.7 Sympathic overactivity in hypertension 
Almost all studies measuring microneurographic sympathetic nerve activity in hypertensive 
patients could demonstrate the central role of sympathetic overactivity [49]. Smith et al. was 
able to show that especially in patients with observable target organ damage MSNA 
increase is more pronounced [50] (Fig. 5). 
 
 
Fig. 5. Microneurographic measurements confirm a significant increase in sympathetic nerve 
activity (MSNA) in patients with hypertension (HT) compared to healthy individuals. An 
increased MSNA can already be found in high-normal blood pressure patients (130-139/85-
89 mmHg) (modified from [50]). 
The underlying conditions of sympathetic overactivity in hypertension are often linked and 
cannot be distinguished from each other. These conditions among others include chronic 
kidney disease, heart failure, obesity and sleep apnea. However, there is evidence that 
sympathetic reactivity might be genetically determined. Children of hypertensive 
individuals show normal MSNA-levels. When subjected to mental stress these children 
show a significantly increased MSNA if compared to children of non-affected parents [51].  
Other hypertensive conditions such as preeclampsia [52] or pulmonary arterial hypertension 
[52] show an increased burst activity in microneurography. 
Today, we have a distinct understanding of the pathogenesis of hypertension induced by 
chronic kidney injury. As seen in figure 1, activation of afferent neurons in the injured 
kidney leads to an increased sympathetic activity through central nervous mechanisms. It is 
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well established that increase of serum norepinephrine levels can indicate chronic kidney 
failure [53]. However, this finding is mostly based on reduced norepinephrine clearance in 
the kidney. Recently, it has been discovered that the kidney also releases a soluble 
monoamine-oxidase (Renalse) which degrades circulating catecholamines and thereby 
might regulate blood pressure [54]. Renalase serum levels are significantly decreased in 
chronic kidney failure. If Renalase actually plays a significant role in hypertension in chronic 
kidney failure patients has not been proven yet.  
As stated above, bilateral nephrectomy is able to normalize MSNA. This can be reproduced 
in an animal model by renal denervation or selective dorsal rhizotomy [55]. Beside increased 
catecholamine levels, increased MSNA is an additional finding in renovascular hypertension 
[56]. The underlying mechanism for renovascular hypertension in renal artery stenosis is 
increased renin release which is dependent on renal innervation. Increase in blood pressure 
can be abolished in a Goldblatt-hypertension animal model (“2 kidney 1 clip”) if the affected 
kidney is denervated [57]. Interestingly, denervation of the non-affected contralateral kidney 
also abolishes hypertension in this model  [58].  
4. Therapeutic approach in sympathetic overactivity  
4.1 Pharmaceutical approach 
In patients with chronic renal failure, the degree of the disease correlates very well with the 
sympathetic activity [59]. An increase of MSNA of 10 burts/min increases the event rate by 60 
%. Concordantly, adverse cardiovascular events are also increased in these patients (Fig. 6.).  
 
 
Fig. 6. Kaplan-Meier curve for adverse cardiovascular events in dependence of MSNA above 
(≥ 36 bursts/min) and below (< 36 bursts/min) the 75th percentile (modified from [59] ).  
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RAAS blockade, through ACE-inhibitors or AT1-blockers, leads to a reduction in the efferent 
sympathetic activity [60, 61]. However, normalization of sympathetic activity can only be 
achieved if a central sympatholytic drug (moxonidine) is added to this treatment [62]. 
Moxonidine has been shown to have renoprotective properties in chronic renal failure and to 
reduce MSNA [63, 64]. This effect was independent from blood pressure reduction. In an 
animal model of chronic kidney failure, monoxidine is able to significantly improve 
histomorphologic and functional renal outcome. It is able to reduce albuminuria and the 
degree of glomerulosclerosis [65]. This might be dependent on an alteration of gene expression 
[14]. Adrenergic receptor activation (ǂ- and ǃ-receptors) is involved in this pathogenesis [66]. 
Therefore it appears feasible that adrenergic receptor inhibitors might be beneficial.   
In patients with resistant hypertension, the suggested blood pressure goal of below 140/90 
mmHg cannot always be achieved using oral antihypertensive medication. Therefore, there 
has been extensive research on alternative approaches for blood pressure control. Due to the 
pivotal role of sympathetic activity in the pathogenesis of hypertension, novel treatment 
strategies have focused on the alteration of sympathetic overactivity in order to control 
blood pressure and reduce overall cardiovascular risk.  
There have been two major advancements in the field of non-pharmaceutical intervention: 
baroreflex activation therapy at the caroid body and catheter-based renal denervation. Each 
of these strategies significantly reduces sympathetic activity and controls blood pressure 
beyond pharmaceutical intervention.  
4.2 Baroreflex activation therapy  
As described above, dysfunction of the baroreceptor reflex causes an increase in sympathetic 
activity in a variety of diseases such as sleep apnea and chronic heart failure. In a canine 
animal model, Lohmeier et al. could demonstrate that activation of the baroreflex at the 
carotid artery by implanted pacemaker was able to reduce blood pressure as well as serum 
catecholamine levels [67, 68]. This approach is currently in clinical evaluation for resistant 
hypertension [69].  Promising data from a clinical trial for baroreflex activation therapy has 
been published recently. In this study, baseline mean blood pressure was 179/105 mmHg 
and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months 
of device therapy, mean blood pressure was reduced by 21/12 mmHg. This result was 
sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 
33/22 mm Hg. The device exhibited a favorable safety profile [70]. 
In the Rheos Pivotal Trial, preliminary results (2010) also show similar results in blood 
pressure control [71]. In this study, subjects were enrolled if systolic blood pressure (SBP) 
was > 160 mmHg, 24-hour ambulatory SBP > 135 mmHg and they were on at least 3 
antihypertensive drugs at maximum doses including a diuretic. 2010, 45 of 55 roll-in 
subjects have reached 6 months follow-up: Prior to baroreflex activation therapy mean 
blood pressure was 178/102 mmHg and post baroreflex activation therapy mean blood 
pressure was 144/87 (p<0.001). A reduction of > 20 mmHg was achieved in 69 % and  
> 30 mmHg in 58 % of subjects. In this study, antihypertensive medication remained 
unchanged during the follow-up period.  
There are some issues of concern regarding this intervention. Previously, baroreflex 
activation therapy required bilateral carotid preparation and implantation of electrodes and 
the corresponding pacemaker aggregate. Due to the approach of bilateral activation, battery 
power of pacemakers lasts only for two years with the need of replacement after this period. 
However, advancements regarding baroreflex activation therapy are made. Recently, a 
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single side baroreflex activation device has been introduced which is currently investigated 
in clinical trials.  
4.3 Renal denervation therapy  
As stated above, renal denervation in animals leads to a reduction of MSNA and blood 
pressure. In 1923, sympathectomy was performed for the first time in order to treat 
hypertension with stenocardia [72]. In 1935, Page and Heuer at the Rockefeller institute 
published data on surgical sympathectomy on blood pressure and renal function [73].   
In 1953, a large study of 1266 cases was published on lumbal sympathectomy. However, this 
procedure was linked with severe side effects such as voiding dysfunction, intestinal 
dysfunction, impotence and orthostatic dysregulation [74]. Due to pharmaceutical 
alternatives, surgical sympathicolysis was replaced by antihypertensive drugs.  
Recently, a novel, minimal-invasive, catheter-based approach is available which selectively 
severs renal nerve fibers at the site of the renal artery [75]. This renal denervation strategy 
can significantly reduce blood pressure in resistant hypertension (Fig. 7) [76]. In a 
multicentre, prospective, randomized trial, patients who had a baseline systolic blood 
pressure of 160 mmHg or more (≥150 mmHg for patients with type 2 diabetes) and were 
treated with at least 3 antihypertensive drugs were enrolled. After a 6-month follow-up 
period after renal denervation, office-based blood pressure measurements in the renal 
denervation group reduced by 32/12 mmHg (SD 23/11, baseline of 178/96 mmHg, 
p<0.0001) without significant side effects. Patients with a glomerular filtration rate of  
< 45 ml/Min/1.73 m2 (MDRD) or renal artery abnormalities were excluded from the study.  
Due to the pathogenesis of sympathetic overactivity in chronic kidney failure, it is feasible 
that this novel approach might also be beneficial in this patient group.  
 
 
Fig. 7. Schematic of renal nerve fibres along the renal artery. Renal denervation is achieved 
by ablation using a catheter which is connected to a radiofrequency generator (picture by 
Ardian/Medtronic). 
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In a preliminary study, renal norepinephrine release was measured. There was a significant 
mean reduction of 47 %. Exemplary, MSNA was measured in a patient before and after 
renal denervation. A marked reduction in nerve activity could be demonstrated (Fig. 8) [77]. 
 
 
 
Fig. 8. Exemplary blood pressure and MSNA in a patient before and after renal denervation. 
There is a significant reduction in blood pressure and burst activity (modified from [77] ). 
5. Summary 
Hypertension is the most significant health burden in modern societies. 25 to 35 % of the 
population suffers from this condition. Due to increasing age, the incidence of hypertension 
will increase in the future.  
Overactivity of the sympathetic nervous system is a striking feature of a variety of 
cardiovascular and renal diseases. There is a distinct correlation between sympathetic 
activity, stage of disease and hypertension. Almost every hypertensive subject shows 
sympathetic overactivity. It correlates well with the cardiovascular event rate (heart failure, 
myocardial infarction, and stroke).  
The kidney plays a pivotal role in the control of sympathetic nerve activity. Baro- and 
chemoreceptors which activate afferent sensory nerves travel from the kidney to the 
sympathetic nuclei of the central nervous system. This can lead to an increase in 
sympathetic activity which leads to an increase of neurotransmitter release in the target 
organs. This axis is especially pronounced in patients with chronic kidney disease. But also 
chronic heart failure, sleep apnea and obesity increase sympathetic nerve activity which can 
be measured by microneurography.  
Pharmaceutical intervention can be achieved with RAAS-blockade (Renin- or ACE-
inhibitors, or AT1-blockers) and peripheral adrenergic receptor antagonists and centrally 
acting sympatholytic drugs.  
If pharmaceutical therapy fails in achieving target blood pressure levels, novel approaches 
in hypertension treatment such as baroreflex activation or renal denervation therapy are 
promising strategies for future treatment which directly inhibit the pacing of sympathetic 
activity.  
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